Year: 2018
Type: preprint
Abstract: Summary The success of immunotherapy has led to a myriad of new clinical trials. Connected to these trials are efforts to discover biomarkers providing mechanistic insight and predictive signatures for personalization. Still, the plethora of immune monitoring technologies can face investigator bias, missing unanticipated cellular responses in limited clinical material. We here present a mass cytometry workflow for standardized, systems-level biomarker discovery in immunotherapy trials. To broadly enumerate human immune cell identity and activity, we established and extensively assessed a reference panel of 33 antibodies to cover major cell subsets, simultaneously quantifying activation and immune checkpoint molecules in a single assay. The resulting assay enumerated ≥ 98% of peripheral immune cells with ≥ 4 positively identifying antigens. Robustness and reproducibility were demonstrated on multiple samples types, across research centers and by orthogonal measurements. Using automated analysis, we monitored complex immune dynamics, identifying signatures in bone-marrow transplantation associated graft-versus-host disease. This validated and available workflow ensures comprehensive immunophenotypic analysis, data comparability and will accelerate biomarker discovery in immunomodulatory therapeutics.
DOI: 10.1101/489765
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: National Science Foundation, Bill and Melinda Gates Foundation, Damon Runyon Cancer Research Foundation, Novartis Foundation, Parker Institute for Cancer Immunotherapy, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Novartis Stiftung für Medizinisch-Biologische Forschung, National Institutes of Health, National Institute on Aging, Stanford Cancer Institute
OpenAlex ID: W2904490301
